JP2001503277A - ウイルス変種およびその検出方法 - Google Patents
ウイルス変種およびその検出方法Info
- Publication number
- JP2001503277A JP2001503277A JP52194498A JP52194498A JP2001503277A JP 2001503277 A JP2001503277 A JP 2001503277A JP 52194498 A JP52194498 A JP 52194498A JP 52194498 A JP52194498 A JP 52194498A JP 2001503277 A JP2001503277 A JP 2001503277A
- Authority
- JP
- Japan
- Prior art keywords
- hbv
- variant
- mutation
- amino acid
- dna polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 18
- 238000001514 detection method Methods 0.000 title description 8
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 146
- 230000002829 reductive effect Effects 0.000 claims abstract description 34
- 239000002777 nucleoside Substances 0.000 claims abstract description 32
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 28
- 230000003612 virological effect Effects 0.000 claims abstract description 27
- 238000003556 assay Methods 0.000 claims abstract description 17
- 230000001900 immune effect Effects 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 15
- 230000035772 mutation Effects 0.000 claims description 105
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 68
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 46
- 239000002773 nucleotide Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 108020004414 DNA Proteins 0.000 claims description 37
- 229960004396 famciclovir Drugs 0.000 claims description 30
- 238000006467 substitution reaction Methods 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 16
- 230000006229 amino acid addition Effects 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 102220028430 rs386352332 Human genes 0.000 claims description 9
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 7
- 229960001627 lamivudine Drugs 0.000 claims description 7
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 7
- 229960001179 penciclovir Drugs 0.000 claims description 7
- 238000007792 addition Methods 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 102220512213 Adenine DNA glycosylase_L526M_mutation Human genes 0.000 claims description 4
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 102220230609 rs1064796737 Human genes 0.000 claims description 4
- 102220075491 rs145238683 Human genes 0.000 claims description 4
- 102220023144 rs387907494 Human genes 0.000 claims description 4
- 102220321276 rs1038089558 Human genes 0.000 claims description 3
- 102220236071 rs143491365 Human genes 0.000 claims description 3
- 102220093943 rs876658576 Human genes 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 230000005257 nucleotidylation Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 102220484483 Ribonuclease H2 subunit C_T3S_mutation Human genes 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 abstract description 16
- 238000002560 therapeutic procedure Methods 0.000 abstract description 14
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 230000036961 partial effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 13
- 108700024845 Hepatitis B virus P Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000700584 Simplexvirus Species 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 102200107877 rs140122268 Human genes 0.000 description 4
- 102200002611 rs431905508 Human genes 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 101150003160 X gene Proteins 0.000 description 3
- KGSIOVLUJYQLKR-UHFFFAOYSA-N [[4-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)butoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 KGSIOVLUJYQLKR-UHFFFAOYSA-N 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960005102 foscarnet Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000522262 Andira inermis Species 0.000 description 1
- KMLONNDXWAQAPV-UHFFFAOYSA-N Angelin Natural products COc1cc(OCC=C(C)C)c2C=CC(=O)Oc2c1C(=O)C=C(C)C KMLONNDXWAQAPV-UHFFFAOYSA-N 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- YSGAPESOXHFTQY-IHRRRGAJSA-N Tyr-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N YSGAPESOXHFTQY-IHRRRGAJSA-N 0.000 description 1
- GNMUGVNEWCZUAA-WOWYBKFKSA-N Umbelliprenin Chemical compound C1=CC(=O)OC2=CC(OC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=CC=C21 GNMUGVNEWCZUAA-WOWYBKFKSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 108700025184 hepatitis B virus X Proteins 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- MVMXJBMAGBRAHD-UHFFFAOYSA-N picoperine Chemical compound C=1C=CC=NC=1CN(C=1C=CC=CC=1)CCN1CCCCC1 MVMXJBMAGBRAHD-UHFFFAOYSA-N 0.000 description 1
- -1 plants Natural products 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220168283 rs140097244 Human genes 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.RNA中間体を経て複製する単離DNAウイルスの変種であって、DNA ポリメラーゼまたはその一部をコードする遺伝子におけるヌクレオチド変異を含 み、該変異がDNAポリメラーゼに対する少なくとも1個のアミノ酸付加、置換 および/または欠失を生じさせるものである変種。 2.RNA中間体を経て複製する単離DNAウイルスの変種であって、表面成 分またはその一部をコードする遺伝子におけるヌクレオチド変異を含み、該変異 が表面成分に対する少なくとも1個のアミノ酸付加、置換および/または欠失を 生じさせるものである変種。 3.RNA中間体を経て複製する単離DNAウイルスの変種であって、少なく とも2つの読み枠の重複部分におけるヌクレオチド変異を含み、該変異が2つの 読み枠の翻訳産物に対するアミノ酸付加、置換および/または欠失を生じさせる ものである変種。 4.該DNAウイルスがB型肝炎ウイルス(HBV)である請求項1または2 または3記載の変種。 5.アミノ酸変異がHBV DNAポリメラーゼのBドメインおよび/または Cドメインに存在する請求項1または3記載の変種。 6.アミノ酸変異がHBV DNAポリメラーゼのBドメインおよび/または Cドメインに対応している請求項2または3記載の変種。 7.HBV DNAポリメラーゼの配列: 中の1個またはそれ以上のアミノ酸における変異を含む請求項1または3記載の 変種。 8.HBV DNAポリメラーゼの配列: 中の1個またはそれ以上のアミノ酸における変異を含む請求項7記載の変種。 9.下記アミノ酸配列:[式中、X1はSまたはA; X2はIまたはV; X3はFまたはL; X4はIまたはL; X5はLまたはVまたはG; X6はPまたはL; X7はLまたはM; X8はIまたはL; X9はCまたはL; X10はAまたはV; X11はSまたはA; X12はMまたはIまたはV; X13はVまたはLまたはM; X14はKまたはR;そして/または X15はSまたはTである] を有するDNAポリメラーゼをコードするヌクレオチド配列を含む変種であって 、ファムシクロビル(ペンシクロビル)および/またはラミブジン(3TC)の ごときヌクレオシドアナログに対する低下した感受性を示す変種。 10.HBV表面抗原のアミノ酸118から169までまたは169から20 7までの1個またはそれ以上のアミノ酸における変異を有する、請求項2または 3記載の変種。 11.下記アミノ酸配列: [式中、X16はQまたはK; X17はYまたはF; X18はGまたはE; X19はRまたはWまたはK; X20はYまたはL; X21はSまたはA; X22はIまたはV; X3はFまたはL; X4はIまたはL; X5はLまたはVまたはG; X6はPまたはL; X7はLまたはM; X8はIまたはL; X9はCまたはL; X10はAまたはV; X11はSまたはA; X12はMまたはIまたはV; X13はVまたはLまたはM; X14はKまたはR;そして/または X15はSまたはTである] を有するDNAポリメラーゼを含み、ファムシクロビル(ペンシクロビル)およ び/またはラミブジン(3TC)のごときヌクレオシドアナログに対する低下し た感受性を示す請求項10記載の変種。 12. Ile509Val、Phe512Leu、Val519Leu、P ro523Leu、Leu526Met、Ile533Leu、Met550V al/Ile、Ser559Thr、Gly498Glu、Arg/Trp49 9Lys、Thr530Serから選択される請求項1または2または3記載の 変種。 13.DNAポリメラーゼをコードするヌクレオチド配列における変異を含み 、ヌクレオシドアナログに対する低下した感受性を示すHBV変種であって、該 変異がDNAポリメラーゼのBドメインおよび/またはCドメインまたはそれら に近い領域におけるアミノ酸付加、置換および/または欠失を生じさせるもので あり、さらに該変異がCドメイン中のYMDDモチーフのみにおけるものではな い変種。 14.ウイルス表面成分をコードするヌクレオチド配列中の変異を含み、該ウ イルス表面成分に対する免疫学的試薬の相互作用活性の低下を示すHBV変種で あって、該変異がHBV DNAポリメラーゼのBドメインおよび/またはCド メインまたはHBV DNAポリメラーゼのBドメインおよび/またはCドメイ ンに近い領域に対応する領域中のウイルス表面成分におけるアミノ酸付加、置換 および/または欠失を生じさせるものである変種。 15.ウイルス表面成分をコードするヌクレオチド配列中の変異を含み、該ウ イルス表面成分に対する免疫学的試薬の低下した相互作用性を示すHBV変種で あって、該変異はHBVのアミノ酸118から169まで、および/または16 9から207までにより画定される領域または機能的に等価な領域中のウイルス 表面成分におけるアミノ酸付加、置換および/または欠失を生じさせるものであ る変種。 16.ゲノム中の重複した読み枠における変異を含み、ヌクレオシドアナログ に対する低下した感受性を示し、HBV表面抗原に特異的な免疫学的試薬に対す る低下した相互作用活性を示すHBV変種であって、該変異がDNAポリメラー ゼのBおよび/またはCドメインにおけるものであり、CドメインのYMDDモ チーフのみにおけるものではなく、さらに該変異がHBV表面抗原のアミノ酸 118から169までおよび/または169から207までに対応する重複領域 または等価な領域におけるものである変種。 17.配列番号:17に示すヌクレオチド配列を有するHBV、あるいは単一 または複数のヌクレオチド付加、置換および/または欠失を有するその誘導体( 例えば、配列番号:17に対して少なくとも60%の類似性を有するヌクレオチ ド配列)。 18.ヌクレオシドアナログに対する低下した感受性および野生型HBV表面 抗原に対する抗体に対する低下した相互作用活性を示す変種HBVであって、以 下の特徴: (i)配列番号:17に示すゲノムのヌクレオチド配列またはそれに対して少な くとも60%の類似性を有する配列; (ii)42℃における低い厳密さの条件下において配列番号:17にハイブリ ダイゼーションしうるヌクレオチド配列; (iii)DNAポリメラーゼおよびHBV表面抗原の読み枠の重複部分におけ る変異;および (iv)HBV DNAポリメラーゼのBおよび/またはCドメイン、およびH BV表面抗原のアミノ酸118から169までおよび/またはそしてさらに16 9から207までに対応する領域における変異の1つまたはそれ以上により特徴 づけられる変種HBV。 19.ヌクレオシドアナログに対する低下した感受性を示すHBVの潜在能力 を調べる方法であって、DNAまたは対応mRNAを該HBVから単離し、つい で、該DNAポリメラーゼのBドメインまたはCドメインまたはそれらに近い領 域中に少なくとも1のアミノ酸置換、欠失および/または付加を生じさせる、H BV DNAポリメラーゼをコードするヌクレオチド配列中の変異に関してスク リーニングを行うことを含み、かかる変異の存在が該ヌクレオシドアナログに対 する耐性の可能性を示すものである方法。 20.HBV表面抗原に対する抗体との低下した相互作用活性を示すHBVの 潜在能力を調べる方法であって、該HBVからDNAまたは対応mRNAを単離 し、該表面抗原のアミノ酸118から169までおよび/または169から20 7までまたは該表面領域中のそれらに近い領域における少なくとも1のアミノ酸 の置換、欠失および/または付加を生じさせる、HBV表面抗原をコードするヌ クレオチド配列中の変異についてスクリーニングすることを含み、かかる変異の 存在が該変異した表面抗原に対する該抗体の相互作用活性低下の可能性を示すも のである方法。 21.アッセイが、Ile509Val、Phe512Leu、Val519 Leu、Pro523Leu、Leu526Met、Ile533Leu、Me t550Val/Ile、Ser559Thr、Gly498Glu、Arg/ Trp499Lys、Thr530Serから選択される変異を検出するもので ある、請求項19または20記載の方法。 22.HBVが変種DNAポリメラーゼをコードしているかどうかを調べる方 法をであって、DNAポリメラーゼのアミノ酸配列を直接的に、あるいはヌクレ オチド配列を介して決定し、ついで、それを下記のアミノ酸配列: と比較することを含み、コンセンサス配列とは異なるアミノ酸の存在が推定上の HBV変種を示すものとなる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU3519 | 1996-11-08 | ||
AUPO3519A AUPO351996A0 (en) | 1996-11-08 | 1996-11-08 | Viral variants and methods for detecting same |
PCT/AU1997/000520 WO1998021317A1 (en) | 1996-11-08 | 1997-08-15 | Viral variants and methods for detecting same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008014075A Division JP2008154590A (ja) | 1996-11-08 | 2008-01-24 | ウイルス変種およびその検出方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001503277A true JP2001503277A (ja) | 2001-03-13 |
JP2001503277A5 JP2001503277A5 (ja) | 2004-12-09 |
Family
ID=3797830
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52194498A Withdrawn JP2001503277A (ja) | 1996-11-08 | 1997-08-15 | ウイルス変種およびその検出方法 |
JP2008014075A Pending JP2008154590A (ja) | 1996-11-08 | 2008-01-24 | ウイルス変種およびその検出方法 |
JP2011276121A Pending JP2012055322A (ja) | 1996-11-08 | 2011-12-16 | ウイルス変種およびその検出方法 |
JP2015018686A Pending JP2015107127A (ja) | 1996-11-08 | 2015-02-02 | ウイルス変種およびその検出方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008014075A Pending JP2008154590A (ja) | 1996-11-08 | 2008-01-24 | ウイルス変種およびその検出方法 |
JP2011276121A Pending JP2012055322A (ja) | 1996-11-08 | 2011-12-16 | ウイルス変種およびその検出方法 |
JP2015018686A Pending JP2015107127A (ja) | 1996-11-08 | 2015-02-02 | ウイルス変種およびその検出方法 |
Country Status (10)
Country | Link |
---|---|
US (4) | US6555311B1 (ja) |
EP (1) | EP0964916B1 (ja) |
JP (4) | JP2001503277A (ja) |
AT (1) | ATE348880T1 (ja) |
AU (1) | AUPO351996A0 (ja) |
CA (1) | CA2270178C (ja) |
DE (1) | DE69737126T2 (ja) |
ES (1) | ES2279542T3 (ja) |
HK (1) | HK1027374A1 (ja) |
WO (1) | WO1998021317A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA973367B (en) * | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
AUPO351996A0 (en) * | 1996-11-08 | 1996-12-05 | Western Health Care Network | Viral variants and methods for detecting same |
USRE40233E1 (en) | 1996-11-08 | 2008-04-08 | Melbourne Health | Viral variants and methods for detecting same |
AUPP706098A0 (en) * | 1998-11-11 | 1998-12-03 | North Western Health Care Network | Biological compositions, components thereof and uses therefor |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
AR028149A1 (es) * | 1999-07-08 | 2003-04-30 | Innogenetics Nv | Deteccion de la resistencia a los farmacos contra la hepatitis b |
AUPQ810900A0 (en) * | 2000-06-09 | 2000-07-06 | Austin and Repatriation Medical Centre, The | Viral variants and methods of using same |
SG90149A1 (en) * | 2000-07-18 | 2002-07-23 | Government Of The Republic Of | Diagnostic assay |
US6697858B1 (en) * | 2000-08-14 | 2004-02-24 | Telephony@Work | Call center |
EP1476543B1 (en) * | 2002-02-07 | 2014-05-14 | Melbourne Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
US7405039B2 (en) | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
AU2002308114A1 (en) | 2002-03-29 | 2003-10-13 | Innogenetics N.V. | Hbv drug resistance drug resistance detection methods |
AU2003213874B2 (en) * | 2002-04-12 | 2008-12-04 | Austin Health | Hepatitis B viral variants with redused susceptibility to nucleoside analogs and uses thereof |
EP2455390A1 (en) | 2002-04-12 | 2012-05-23 | Melbourne Health | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
CA2486420C (en) | 2002-06-14 | 2014-04-15 | Gen-Probe Incorporated | Compositions and methods for detecting hepatitis b virus |
AU2003277208A1 (en) * | 2002-10-01 | 2004-04-23 | Georgetown University | Diagnostic for long term response of hbv carrier to 3tc therapy |
AU2006224788B2 (en) | 2005-03-15 | 2012-08-16 | Justus-Liebig-Universitat Giessen | Variants of Hepatitis B virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof |
ES2494840T3 (es) | 2005-03-15 | 2014-09-16 | Fujirebio Europe N.V. | Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas |
SG161255A1 (en) | 2005-04-08 | 2010-05-27 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
AU2006230802A1 (en) | 2005-04-08 | 2006-10-12 | Austin Health | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof |
KR100790226B1 (ko) | 2005-11-03 | 2008-01-02 | 연세대학교 산학협력단 | 독성 간염 유발 감수성을 검출하는 방법 |
US20230148447A9 (en) | 2008-12-11 | 2023-05-11 | Pacific Biosciences Of California, Inc. | Classification of nucleic acid templates |
US9175338B2 (en) | 2008-12-11 | 2015-11-03 | Pacific Biosciences Of California, Inc. | Methods for identifying nucleic acid modifications |
EP2370598B1 (en) * | 2008-12-11 | 2017-02-15 | Pacific Biosciences Of California, Inc. | Classification of nucleic acid templates |
EP2694686B2 (en) | 2011-04-06 | 2023-07-19 | The University of Chicago | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5-METHYLCYTOSINE (5mC) |
US9238836B2 (en) | 2012-03-30 | 2016-01-19 | Pacific Biosciences Of California, Inc. | Methods and compositions for sequencing modified nucleic acids |
WO2013163207A1 (en) | 2012-04-24 | 2013-10-31 | Pacific Biosciences Of California, Inc. | Identification of 5-methyl-c in nucleic acid templates |
CA3160755A1 (en) * | 2019-12-07 | 2021-06-10 | Sonja Ingrid BUSCHOW | Treatment of diseases related to hepatitis b virus |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595739A (en) * | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
ZA973367B (en) * | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
AUPO351996A0 (en) * | 1996-11-08 | 1996-12-05 | Western Health Care Network | Viral variants and methods for detecting same |
USRE40233E1 (en) * | 1996-11-08 | 2008-04-08 | Melbourne Health | Viral variants and methods for detecting same |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
AUPQ810900A0 (en) * | 2000-06-09 | 2000-07-06 | Austin and Repatriation Medical Centre, The | Viral variants and methods of using same |
US7405039B2 (en) * | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
AU2002308114A1 (en) * | 2002-03-29 | 2003-10-13 | Innogenetics N.V. | Hbv drug resistance drug resistance detection methods |
EP2455390A1 (en) * | 2002-04-12 | 2012-05-23 | Melbourne Health | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
KR20130049210A (ko) * | 2003-10-21 | 2013-05-13 | 멜버른 헬스 | Hbv 변이체 검출 및 응용 |
AU2006224788B2 (en) * | 2005-03-15 | 2012-08-16 | Justus-Liebig-Universitat Giessen | Variants of Hepatitis B virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof |
ES2494840T3 (es) * | 2005-03-15 | 2014-09-16 | Fujirebio Europe N.V. | Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas |
SG161255A1 (en) * | 2005-04-08 | 2010-05-27 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
AU2006230802A1 (en) * | 2005-04-08 | 2006-10-12 | Austin Health | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof |
WO2007140522A1 (en) * | 2006-06-06 | 2007-12-13 | Melbourne Health | Detection and use of antiviral resistance mutations |
-
1996
- 1996-11-08 AU AUPO3519A patent/AUPO351996A0/en not_active Abandoned
-
1997
- 1997-08-15 DE DE69737126T patent/DE69737126T2/de not_active Expired - Lifetime
- 1997-08-15 AT AT97934385T patent/ATE348880T1/de active
- 1997-08-15 CA CA2270178A patent/CA2270178C/en not_active Expired - Lifetime
- 1997-08-15 JP JP52194498A patent/JP2001503277A/ja not_active Withdrawn
- 1997-08-15 ES ES97934385T patent/ES2279542T3/es not_active Expired - Lifetime
- 1997-08-15 WO PCT/AU1997/000520 patent/WO1998021317A1/en active IP Right Grant
- 1997-08-15 EP EP97934385A patent/EP0964916B1/en not_active Expired - Lifetime
-
1999
- 1999-05-06 US US09/306,420 patent/US6555311B1/en not_active Ceased
-
2000
- 2000-06-22 HK HK00103809A patent/HK1027374A1/xx not_active IP Right Cessation
-
2002
- 2002-10-01 US US10/260,451 patent/US20030124096A1/en not_active Abandoned
-
2008
- 2008-01-24 JP JP2008014075A patent/JP2008154590A/ja active Pending
- 2008-05-09 US US12/117,869 patent/US20100203506A1/en not_active Abandoned
-
2011
- 2011-12-16 JP JP2011276121A patent/JP2012055322A/ja active Pending
-
2012
- 2012-07-12 US US13/547,392 patent/US20130171620A1/en not_active Abandoned
-
2015
- 2015-02-02 JP JP2015018686A patent/JP2015107127A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69737126T2 (de) | 2007-10-04 |
EP0964916A1 (en) | 1999-12-22 |
JP2012055322A (ja) | 2012-03-22 |
US20130171620A1 (en) | 2013-07-04 |
WO1998021317A1 (en) | 1998-05-22 |
CA2270178C (en) | 2012-06-12 |
EP0964916B1 (en) | 2006-12-20 |
EP0964916A4 (en) | 2001-09-26 |
US20030124096A1 (en) | 2003-07-03 |
US20100203506A1 (en) | 2010-08-12 |
HK1027374A1 (en) | 2001-01-12 |
US6555311B1 (en) | 2003-04-29 |
AUPO351996A0 (en) | 1996-12-05 |
ES2279542T3 (es) | 2007-08-16 |
JP2008154590A (ja) | 2008-07-10 |
JP2015107127A (ja) | 2015-06-11 |
CA2270178A1 (en) | 1998-05-22 |
DE69737126D1 (de) | 2007-02-01 |
ATE348880T1 (de) | 2007-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001503277A (ja) | ウイルス変種およびその検出方法 | |
Yeh et al. | Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy | |
Tillmann et al. | Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation | |
Sterneck et al. | Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation | |
US7931907B2 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same | |
Liu et al. | Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences | |
CN101203528A (zh) | 对核苷类似物敏感性降低的乙型肝炎病毒变异体及其用途 | |
EP1476543B1 (en) | Viral variants with altered susceptibility to nucleoside analogs and uses thereof | |
US8211633B2 (en) | Viral variants with altered susceptibility to nucleoside analogs and uses thereof | |
Enomoto et al. | Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug‐resistant variants during lamivudine therapy: Analyses of the polymerase gene and full‐length sequences | |
AU734831B2 (en) | Viral variants and methods for detecting same | |
USRE40233E1 (en) | Viral variants and methods for detecting same | |
Liu et al. | Origin of serum hepatitis B virus in acute exacerbation: comparison with HBV in the liver and from other exacerbation | |
Lampertico et al. | Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon | |
Petzold et al. | Infection chains and evolution rates of hepatitis B virus in cardiac transplant recipients infected nosocomially | |
JP4398379B2 (ja) | B型肝炎ウイルスの薬物抵抗性を識別する方法 | |
Zoulim et al. | Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? | |
AU780978B2 (en) | Viral variants and methods for detecting same | |
AU2001263672B2 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same | |
AU2001263672A1 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040311 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070330 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070719 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080124 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080221 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100726 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100729 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100901 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100924 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101006 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110511 |